News | September 27, 2022
Novartis unveils new focused strategy
Transformation to pure-play Innovative Medicines company nears completion
Transformation to pure-play Innovative Medicines company nears completion
Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities
TMA will leverage Syntegra's synthetic data engine to accelerate the building of predictive diagnostic algorithms
The partnership aims to enhance HotSpot's drug discovery and development efforts by incorporating GOSTAR's high-quality, annotated datasets into HotSpot's machine learning (ML) and artificial intelligence (AI) models
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
Pioneering Medicines and Novo Nordisk Bio Innovation Hub will leverage Flagship Pioneering’s bioplatform companies to create a portfolio of research programmes within cardiometabolic and rare diseases
The plan is to advance innovative therapies to drug-resistant cancers
Subscribe To Our Newsletter & Stay Updated
